Skip to Content

Institute for Applied Cancer Science

Lead Discovery and Biotesting

The lead discovery and biotesting group designs, validates, implements and optimizes robust state-of-the-art biochemical, biophysical, and cell-based assays for novel cancer drug targets to guide medicinal chemistry efforts through the drug discovery process to clinical candidate nomination. These assays identify active chemical or biological entities, characterize them with respect to potency and selectivity and determine their mode of action.

Our lead discovery scientists have extensive experience with diverse target classes using a wide range of assay technologies and make extensive use of automation to streamline their workflow to ensure consistency of data. By generating highly reproducible, quantitative data in a timely manner, project team members enable rapid iterative lead optimization at IACS.

The lead discovery and biotesting team is led by Mary Geck Do, Ph.D.

© 2014 The University of Texas MD Anderson Cancer Center